科伦药业：罗替高汀贴片获得药品注册批准

Core Viewpoint - Kolun Pharmaceutical has received drug registration approval from the National Medical Products Administration for its chemical drug "Rotigotine Patch," which is used for the treatment of early idiopathic Parkinson's disease symptoms and signs [1] Group 1 - The "Rotigotine Patch" was developed by UCB Pharma and was first approved in the European Union in 2006 [1] - The drug was imported into China in 2018, indicating its established presence in the market prior to this approval [1] - The approval marks a significant milestone for Kolun Pharmaceutical, enhancing its product portfolio in the neurology sector [1]